CRISPR-Barcoding for Intratumor Genetic Heterogeneity Modeling and Functional Analysis of Oncogenic Driver Mutations

Molecular Cell

Volumn 63, Issue 3, 2016, Pages 526-538

  Guernet, Alexis ^a,b   Mungamuri, Sathish Kumar ^c   Cartier, Dorthe ^a,b   Sachidanandam, Ravi ^c   Jayaprakash, Anitha ^c   Adriouch, Sahil ^b   Vezain, Myriam ^b   Charbonnier, Françoise ^b   Rohkin, Guy ^c   Coutant, Sophie ^b   Yao, Shen ^c   Ainani, Hassan ^a,b   Alexandre, David ^a,b   Tournier, Isabelle ^b   Boyer, Olivier ^b,d   Aaronson, Stuart A ^c   Anouar, Youssef ^a,b   Grumolato, Luca ^a,b  

^a UNIVERSITÉ DE ROUEN   (France)

^b UNIVERSITY OF ROUEN   (France)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 6 (1 THIANTHRENYL) 4 PYRANONE; 5 CHLORO 4 [[2 (ISOPROPYLSULFONYL)PHENYL]AMINO] 2 [[2 METHOXY 4 [4 (4 METHYL 1 PIPERAZINYL) 1 PIPERIDINYL]PHENYL]AMINO]PYRIMIDINE; CASPASE 9; DNA; GEFITINIB; N [3 [[5 CHLORO 2 [[2 METHOXY 4 (4 METHYL 1 PIPERAZINYL)PHENYL]AMINO] 4 PYRIMIDINYL]OXY]PHENYL]ACRYLAMIDE; TRAMETINIB; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; TUMOR MARKER;

ARTICLE; CANCER CELL; CANCER RESISTANCE; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; DNA BARCODING; DNA MODIFICATION; GENE INACTIVATION; GENE MUTATION; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NEUROBLASTOMA CELL; NON SMALL CELL LUNG CANCER; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; SEQUENCE ANALYSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CLONE; CELL LINEAGE; CRISPR CAS SYSTEM; DNA MUTATIONAL ANALYSIS; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENE EDITING; GENETIC PREDISPOSITION; GENETICS; HCT 116 CELL LINE; HEK293 CELL LINE; HIGH THROUGHPUT SEQUENCING; LUNG NEOPLASMS; MALE; MCF-7 CELL LINE; METABOLISM; MULTIPLEX POLYMERASE CHAIN REACTION; ONCOGENE; PATHOLOGY; PHENOTYPE; POINT MUTATION; PROCEDURES; SCID MOUSE; TIME FACTOR; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINEAGE; CLONE CELLS; CRISPR-CAS SYSTEMS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GENE EDITING; GENETIC HETEROGENEITY; GENETIC PREDISPOSITION TO DISEASE; HCT116 CELLS; HEK293 CELLS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LUNG NEOPLASMS; MALE; MCF-7 CELLS; MICE, SCID; MULTIPLEX POLYMERASE CHAIN REACTION; ONCOGENES; PHENOTYPE; POINT MUTATION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TIME FACTORS; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84992747353     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2016.06.017     Document Type: Article

References (51)

1. Avraham, R., Yarden, Y., Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat. Rev. Mol. Cell Biol. 12 (2011), 104–117.
2. Bhang, H.E., Ruddy, D.A., Krishnamurthy Radhakrishna, V., Caushi, J.X., Zhao, R., Hims, M.M., Singh, A.P., Kao, I., Rakiec, D., Shaw, P., et al. Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. Nat. Med. 21 (2015), 440–448.
3. Boettcher, M., McManus, M.T., Choosing the right tool for the job: RNAi, TALEN, or CRISPR. Mol. Cell 58 (2015), 575–585.
4. Cheung, N.K., Dyer, M.A., Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat. Rev. Cancer 13 (2013), 397–411.
5. Choi, P.S., Meyerson, M., Targeted genomic rearrangements using CRISPR/Cas technology. Nat. Commun., 5, 2014, 3728.
6. Chong, C.R., Jänne, P.A., The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat. Med. 19 (2013), 1389–1400.
7. Chu, V.T., Weber, T., Wefers, B., Wurst, W., Sander, S., Rajewsky, K., Kühn, R., Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. Nat. Biotechnol. 33 (2015), 543–548.
8. Clevers, H., The cancer stem cell: premises, promises and challenges. Nat. Med. 17 (2011), 313–319.
9. Clevers, H., Nusse, R., Wnt/β-catenin signaling and disease. Cell 149 (2012), 1192–1205.
10. DeKelver, R.C., Choi, V.M., Moehle, E.A., Paschon, D.E., Hockemeyer, D., Meijsing, S.H., Sancak, Y., Cui, X., Steine, E.J., Miller, J.C., et al. Functional genomics, proteomics, and regulatory DNA analysis in isogenic settings using zinc finger nuclease-driven transgenesis into a safe harbor locus in the human genome. Genome Res. 20 (2010), 1133–1142.
11. Diaz, L.A. Jr., Williams, R.T., Wu, J., Kinde, I., Hecht, J.R., Berlin, J., Allen, B., Bozic, I., Reiter, J.G., Nowak, M.A., et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486 (2012), 537–540.
12. Ding, L., Wendl, M.C., McMichael, J.F., Raphael, B.J., Expanding the computational toolbox for mining cancer genomes. Nat. Rev. Genet. 15 (2014), 556–570.
13. Doudna, J.A., Charpentier, E., Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science, 346, 2014, 1258096.
14. Dow, L.E., O'Rourke, K.P., Simon, J., Tschaharganeh, D.F., van Es, J.H., Clevers, H., Lowe, S.W., Apc restoration promotes cellular differentiation and reestablishes crypt homeostasis in colorectal cancer. Cell 161 (2015), 1539–1552.
15. Fu, Y., Foden, J.A., Khayter, C., Maeder, M.L., Reyon, D., Joung, J.K., Sander, J.D., High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat. Biotechnol. 31 (2013), 822–826.
16. Gerlinger, M., Rowan, A.J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366 (2012), 883–892.
17. Gillies, R.J., Verduzco, D., Gatenby, R.A., Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat. Rev. Cancer 12 (2012), 487–493.
18. Greaves, M., Maley, C.C., Clonal evolution in cancer. Nature 481 (2012), 306–313.
19. Hallberg, B., Palmer, R.H., Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat. Rev. Cancer 13 (2013), 685–700.
20. Hata, A.N., Niederst, M.J., Archibald, H.L., Gomez-Caraballo, M., Siddiqui, F.M., Mulvey, H.E., Maruvka, Y.E., Ji, F., Bhang, H.E., Krishnamurthy Radhakrishna, V., et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat. Med. 22 (2016), 262–269.
21. Hsu, P.D., Lander, E.S., Zhang, F., Development and applications of CRISPR-Cas9 for genome engineering. Cell 157 (2014), 1262–1278.
22. Huveneers, S., Danen, E.H., Adhesion signaling - crosstalk between integrins, Src and Rho. J. Cell Sci. 122 (2009), 1059–1069.
23. Jackson, S.P., Bartek, J., The DNA-damage response in human biology and disease. Nature 461 (2009), 1071–1078.
24. Jänne, P.A., Yang, J.C., Kim, D.W., Planchard, D., Ohe, Y., Ramalingam, S.S., Ahn, M.J., Kim, S.W., Su, W.C., Horn, L., et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N. Engl. J. Med. 372 (2015), 1689–1699.
25. Jiang, H., Reinhardt, H.C., Bartkova, J., Tommiska, J., Blomqvist, C., Nevanlinna, H., Bartek, J., Yaffe, M.B., Hemann, M.T., The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev. 23 (2009), 1895–1909.
26. Lin, Y., Cradick, T.J., Brown, M.T., Deshmukh, H., Ranjan, P., Sarode, N., Wile, B.M., Vertino, P.M., Stewart, F.J., Bao, G., CRISPR/Cas9 systems have off-target activity with insertions or deletions between target DNA and guide RNA sequences. Nucleic Acids Res. 42 (2014), 7473–7485.
27. Maddalo, D., Manchado, E., Concepcion, C.P., Bonetti, C., Vidigal, J.A., Han, Y.C., Ogrodowski, P., Crippa, A., Rekhtman, N., de Stanchina, E., de Stanchina, E., et al. In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. Nature 516 (2014), 423–427.
28. Maruyama, T., Dougan, S.K., Truttmann, M.C., Bilate, A.M., Ingram, J.R., Ploegh, H.L., Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. Nat. Biotechnol. 33 (2015), 538–542.
29. McGranahan, N., Swanton, C., Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell 27 (2015), 15–26.
30. Merlo, L.M., Pepper, J.W., Reid, B.J., Maley, C.C., Cancer as an evolutionary and ecological process. Nat. Rev. Cancer 6 (2006), 924–935.
31. Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486 (2012), 532–536.
32. Muller, P.A., Vousden, K.H., Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell 25 (2014), 304–317.
33. Nguyen, L.V., Cox, C.L., Eirew, P., Knapp, D.J., Pellacani, D., Kannan, N., Carles, A., Moksa, M., Balani, S., Shah, S., et al. DNA barcoding reveals diverse growth kinetics of human breast tumour subclones in serially passaged xenografts. Nat. Commun., 5, 2014, 5871.
34. Nowell, P.C., The clonal evolution of tumor cell populations. Science 194 (1976), 23–28.
35. Obenauf, A.C., Zou, Y., Ji, A.L., Vanharanta, S., Shu, W., Shi, H., Kong, X., Bosenberg, M.C., Wiesner, T., Rosen, N., et al. Therapy-induced tumour secretomes promote resistance and tumour progression. Nature 520 (2015), 368–372.
36. Pao, W., Chmielecki, J., Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat. Rev. Cancer 10 (2010), 760–774.
37. Paquet, D., Kwart, D., Chen, A., Sproul, A., Jacob, S., Teo, S., Olsen, K.M., Gregg, A., Noggle, S., Tessier-Lavigne, M., Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9. Nature 533 (2016), 125–129.
38. Pfaffl, M.W., A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res., 29, 2001, e45.
39. Polakis, P., Wnt signaling in cancer. Cold Spring Harb. Perspect. Biol., 4, 2012, a008052.
40. Ran, F.A., Hsu, P.D., Wright, J., Agarwala, V., Scott, D.A., Zhang, F., Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8 (2013), 2281–2308.
41. Richardson, C.D., Ray, G.J., DeWitt, M.A., Curie, G.L., Corn, J.E., Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA. Nat. Biotechnol. 34 (2016), 339–344.
42. Shah, S.P., Roth, A., Goya, R., Oloumi, A., Ha, G., Zhao, Y., Turashvili, G., Ding, J., Tse, K., Haffari, G., et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486 (2012), 395–399.
43. Soda, M., Choi, Y.L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S., Watanabe, H., Kurashina, K., Hatanaka, H., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448 (2007), 561–566.
44. Solomon, B., Wilner, K.D., Shaw, A.T., Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer. Clin. Pharmacol. Ther. 95 (2014), 15–23.
45. Sullivan, K.D., Padilla-Just, N., Henry, R.E., Porter, C.C., Kim, J., Tentler, J.J., Eckhardt, S.G., Tan, A.C., DeGregori, J., Espinosa, J.M., ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53. Nat. Chem. Biol. 8 (2012), 646–654.
46. Tricker, E.M., Xu, C., Uddin, S., Capelletti, M., Ercan, D., Ogino, A., Pratilas, C.A., Rosen, N., Gray, N.S., Wong, K.K., Jänne, P.A., Combined EGFR/MEK inhibition prevents the emergence of resistance in EGFR-mutant lung cancer. Cancer Discov. 5 (2015), 960–971.
47. Turke, A.B., Zejnullahu, K., Wu, Y.L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17 (2010), 77–88.
48. Valentini, A., Pompanon, F., Taberlet, P., DNA barcoding for ecologists. Trends Ecol. Evol. 24 (2009), 110–117.
49. Vassilev, L.T., Vu, B.T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303 (2004), 844–848.
50. Yu, C., Liu, Y., Ma, T., Liu, K., Xu, S., Zhang, Y., Liu, H., La Russa, M., Xie, M., Ding, S., Qi, L.S., Small molecules enhance CRISPR genome editing in pluripotent stem cells. Cell Stem Cell 16 (2015), 142–147.
51. Zhou, W., Ercan, D., Chen, L., Yun, C.H., Li, D., Capelletti, M., Cortot, A.B., Chirieac, L., Iacob, R.E., Padera, R., et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 462 (2009), 1070–1074.